A. Lorentzos

发表

A randomised phase II study of carmustine alone or in combination with tomour necrosis factor in patients with advanced melanoma

M. Gore, C. Viner, M. O'Brien, 2004, Cancer Chemotherapy and Pharmacology.

The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck.

K. Maclennan, M. Gore, M. O'Brien, 1994, European journal of cancer. Part B, Oral oncology.

Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck.

K. Maclennan, M. Gore, D. Henderson, 1993, European journal of cancer. Part B, Oral oncology.

A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.

M. Gore, Jenny C. Chang, R. A’Hern, 1994, European journal of cancer.

Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck.

K. Maclennan, M. Gore, M. O'Brien, 1992, British Journal of Cancer.

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.

M. Gore, M. Nicolson, R. A’Hern, 1996, British Journal of Cancer.

Infectious complications of subcutaneous interleukin-2 and interferon-alpha

M. Gore, I. Cropley, A. Jones, 1992, The Lancet.

Tamoxifen and chemotherapy for refractory metastatic malignant melanoma.

M. Gore, M. McKeage, A. Lorentzos, 1993, The New England journal of medicine.

Infectious complications of interleukin 2 therapy.

M. Gore, B. Jameson, E. Ellis, 1990, Cytokine.